

Voting Members Present:

A-ME (Chair)
K-BIOL (Interim Chair)
K-NAM
D-NAM
T-ORIA
S-BME
S-BIOL
KA-ORIA

Voting Members Absent:

K-EHS

Non-voting Attendees:

KS-ORIA

The full Committee roster is posted publicly on the Georgia Tech website. All requests from the public to join a Georgia Tech IBC meeting are considered upon request. No such requests were received for this meeting.

1. **A quorum being present, the meeting was called to order at 11:00 am.**
2. **Approval of August 6, 2026, Minutes**
The August IBC minutes were sent to the committee for review. No modifications were requested.

Motion: Approve the minutes as written.

Approve: Five

Disapprove: None

Abstain: Three

3. **Registrations/Amendments for Discussion at Today's Meeting**

EMELIANOV-R100174 (Renewal)

Title: Producing lentivirus containing Chimeric Antigen Receptors for T cell transduction

Funding: NIH

Category: Non-Exempt, BSL-2, ABSL-1, Section III-F-8, II-D-1a

Discussion Leaders: A-ME, D-NAM

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to develop an advanced, in vivo, noninvasive, molecular specific imaging technology capable of immediate and accurate assessment of CAR-T cell delivery into primary tumors in real time, and to perform and evaluate immunotherapy. The proposed use of a CAR-T cell production component, receptor proteins and marker proteins indicates that this work should be classified as Non-Exempt, BSL-2, ABSL-1, Section III-F-8, II-D-1a. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described in this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee found that there needs to be clarification regarding how blue

fluorescent protein is involved in the project. Also, Section 3.5 needed more detail. The committee requested details on safety precautions for working with the proposed vectors, and to clearly state that the lentiviral vectors to be used are second-generation. There was also a request by the committee to clarify the ABSL classification with EHS due to conflicting comments.

Motion: Return the protocol to the PI to revise, then reassign to the Discussion leaders for a second review.

Approve: Eight

Disapprove: None

Abstain: None

STOLFI-R100096 (Renewal)

Title: Regulation of cell behavior in the tunicate Ciona

Funding: NIH, NSF

Category: Non-Exempt, BSL-2, Section III-D-4, III-E, III-F-8

Discussion Leaders: S-BME, T-ORIA

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to use genetic manipulation of marine macroinvertebrates to study genetic networks that control cell behaviors in the developing nervous system. This project is also associated with an undergraduate capstone course. The proposed use of genetic editing components, transcription factors, signaling molecules, cellular effectors and fluorescent proteins indicates that this work should be classified Non-Exempt, BSL-2, Section III-D-4, III-E, III-F-8. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described in this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee requested that the PI include the class roster on the protocol so that training can be verified. A reminder was provided for the PI to add any new students that join the course and will be working with the materials. Also, some of the vector maps appeared to be unreadable and should be converted and saved as PDF files to allow for clear review. Safety precautions for working with each vector should also be included as well.

Motion: Return protocol to the PI to revise, then return to ORIA to confirm that changes were adequately addressed for approval.

Approve: Eight

Disapprove: None

Abstain: None

DIXON-R100027 (Renewal)

Title: Models of Lymphedema and Lymphatic Injury to Investigate Disease Progression and Evaluate Therapeutic Strategies

Funding: NIH, ARPA-H

Category: Non-Exempt, BSL-2, ABSL-2, Sections III-D, III-D-1-a, III-D-3-a, III-D-4

Discussion Leaders: S-BIOL, K-NAM

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to study the delivery capabilities of nanoparticles carrying DNA and/or RNA, in which thousands of chemically distinct nanoparticles are barcoded, and then assayed in vitro and in vivo using high throughput techniques developed in the lab. The proposed use of genetic editors, inhibitors, activators and fusion proteins indicate that this work should be classified as Non-Exempt, BSL-2, ABSL-2, Sections III-D, III-D-1-a, III-D-3-a, III-D-4. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described in this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee had no major safety concerns with this protocol. However, the committee requested that ORIA confirm that the two animal protocols attached to protocol are currently approved.

Motion: Approve the protocol as written.

Approve: Eight

Disapprove: None

Abstain: None

BRYKSIN-R100186 (Renewal)

Title: DNA, RNA in-vitro and in-vivo Molecular Evolution

Funding: Discretionary

Category: Non-Exempt, BSL-2, Section III-E; III-F-1; III-F-2, III-F-8 (Appendix C-II & C-III)

Discussion Leaders: K-BIOL, KA-ORIA

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to offer a variety of molecular biology services to Georgia Tech labs. The proposed genes of interest, fluorescent proteins, Gibson inserts, transposable elements, DNA polymerases, reverse transcriptase and ssDNA binding proteins indicates that this work should be classified as Non-Exempt, BSL-2, Section III-E; III-F-1; III-F-2, III-F-8 (Appendix C-II & C-III). The Committee found that the facilities, procedures, practices, training, and expertise of personnel described in this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee had no concerns with this protocol.

Motion: Approve the protocol as written.

Approve: Eight

Disapprove: None

Abstain: None

4. Other business

Upcoming Revision to NIH Guidelines Regarding IBC/BMSC Roles and Responsibilities

- ORIA shared with the committee a draft NIH policy that is intended to replace the NIH Guidelines. Guidance proposes that some functions of the IBC and BMSC may be combined in the future. ORIA will provide an update of the required changes to the committee at a later meeting. The hope is that most changes are administrative rather than involving the full committee.

Next meeting October 1, 2026